Anti-Human IL-33 Reference Antibody (Etokimab, RUO)

SKU: HF543016

Size:100ug

Description:ANB020, now called etokimab, is currently in phase 2a testing in eczema, which is also known as atopic dermatitis. Scientists from the Medical Research Council Human Immunology Unit at the University of Oxford released data from 12 patients showing that 83% who were treated with etokimab reported a reduction in disease severity after 29 days. Etokimab, an anti-IL-33 biologic, has previously demonstrated a good safety profile and favorable pharmacodynamic properties in many clinical studies. Etokimab is designed to block interleukin-33 (IL-33), an immune-signaling molecule. In peanut allergy, the body overreacts to peanuts as IL-33 activates an antibody called immunoglobin E. These antibodies cause allergic response such as mouth itchiness, hives, breathing difficulties and potentially fatal anaphylactic shock.

Host species:Humanized

Tested applications:

Species reactivity:Human

Form:Liquid

Storage buffer:0.01M PBS, pH 7.4.

Purity:>95% as determined by SDS-PAGE.

Clonality:Monoclonal

Isotype:IgG1-kappa

Applications:ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Target:NF-HEV, IL-1F11, C9orf26, IL-33, Interleukin-1 family member 11, IL33, Nuclear factor from high endothelial venules, NFHEV, Interleukin-33, IL1F11

Purification:Protein A/G purified from cell culture supernatant.

Endotoxin level:Please contact us for this information.

Expression system:Mammalian Cells

Accession:O95760

Stability and Storage:Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Reconstitution:

Background:

Alternative Names:ANB020, 2022981-44-6, IL33

Clone ID:

Species:Human

Note:For research use only. Not suitable for clinical or therapeutic use.